Capricor Therapeutics, Inc. (CAPR) short interest & options flow
NASDAQCAPR enters the final stretch before the November 22 FDA decision on deramiocel carrying nearly 40% short interest, a sharply rising put/call ratio, and two institutional holders who have just exited entirely. Short interest has pulled back from its late-October peak but remains extreme. At 39.9% of the free float, the bearish position is down 13% on the week as some shorts trimmed…
CAPR upgraded to Buy by Jones Trading with $25 price target, up from Hold rating. Stock at $10.24, down 8.7% today but up 37% over one month ahead of FDA decision on deramiocel November 22.
- Market cap
- $489M
- Next earnings
- 15 Mar 2027
Key data as of 20 Nov 2026

Latest signals on CAPR
- Analyst
CAPR upgraded to Buy by Jones Trading with $25 price target, up from Hold rating. Stock at $10.24, down 8.7% today but up 37% over one month ahead of FDA decision on deramiocel November 22.
CAPR news and analysis
RSSNo long-form analysis yet for CAPR. Pulse alerts and the live data picture are available on ORTEX.
Open CAPR on ORTEX →Want the live picture for CAPR?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAPR — free to start on ORTEX.
Sign up for free →Open CAPR on ORTEX